Robotic Endoscopy Market

Overview

The global Robotic Endoscopy Market was valued at USD 1 billion in 2025 and is projected to reach USD 3.80 billion by 2034, growing at a CAGR of 16% during the forecast period (2026–2034). The market is driven by rising lung nodule detection through screening programs, the need for higher diagnostic accuracy in hard-to-reach anatomy, and growing hospital interest in platforms that reduce physician fatigue and procedure-to-procedure variability, together with steady improvements in navigation software and single-use instrument design. The market is shifting from conventional, manual, operator-dependent scope handling toward software-guided platforms that combine robotic articulation, shape sensing or electromagnetic tracking, and integrated imaging. Lung biopsy led this transition, and the same logic is now being applied to colonoscopy, endoscopic submucosal dissection, and ureteroscopy.  Government initiatives such as the US Preventive Services Task Force 2021 recommendation for annual low-dose CT lung cancer screening in adults aged 50 to 80 years with a 20 pack-year smoking history are enlarging the group of patients whose lung nodules need tissue diagnosis. Regulators are also shortening the path to market, with the US FDA offering its Safer Technologies Program for devices such as endoluminal robots and China's NMPA operating a special review pathway for innovative medical devices. By Region, North America held the largest share of the market in 2025, led by early regulatory clearances, a large installed base of robotic bronchoscopy systems, and established payment for lung nodule biopsy in the United States. Asia-Pacific is expected to be the fastest-growing region during the forecast period, as China, Japan, South Korea, and India expand lung cancer screening, register locally built robotic endoscopes, and invest in hospital modernization.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Artificial Intelligence and Imaging Integration Emerging as a Transformational Trend in Robotic Endoscopy

• Navigation software is becoming the main point of competition in robotic endoscopy. Early platforms focused on steering hardware, while current releases concentrate on planning, registration, and real-time correction of anatomical movement. Hospitals now judge systems by how well software narrows the gap between the pre-procedure scan and the live airway.
• Cone-beam CT, digital tomosynthesis, and augmented fluoroscopy are being linked directly to the robot, so the clinician can confirm that a tool sits inside the lesion without leaving the procedure. Vendors are also designing single-use scopes to remove reprocessing steps and cross-contamination risk.
• Adoption is spreading from academic centers to community hospitals and ambulatory sites, which want shorter learning curves and flexible room setups. This pushes manufacturers toward compact carts, open compatibility with existing C-arms, and structured training programs. Newer entrants compete on lower radiation exposure and easier integration rather than matching incumbents feature for feature.
• Intuitive received US FDA clearance for Ion software that adds artificial intelligence across the full navigation workflow, aimed at correcting CT-to-body divergence in real time. The company reported more than 900 Ion systems in hospitals across 10 countries as of June 30, 2025, which is the installed base receiving these updates.

KEY MARKET DRIVER

Rising Lung and Gastrointestinal Cancer Burden Driving Demand for Precise Robotic Endoscopic Procedures

• Cancer incidence is the clearest demand signal. IARC's GLOBOCAN 2022 estimates recorded nearly 2.5 million new lung cancer cases and 1.8 million lung cancer deaths worldwide, while colorectal cancer made up 9.6% of all new cancer cases. Many of these diagnoses begin with an endoscopic or image-guided tissue sample, which keeps procedure demand tied to cancer detection.
• Physician workforce strain adds a second push. Manual bronchoscopy, colonoscopy, and endoscopic resection demand long periods of awkward posture and fine hand control, which raises fatigue and injury risk for specialists. Robotic handles and consoles move that effort to a stable seated position, helping hospitals retain experienced staff and standardize results across operators.
• Hospitals also value consistency. A robotic platform that holds a scope tip steady and repeats the same motion lets newer operators reach small targets that once took years of practice. Administrators see this as a way to raise biopsy yield, shorten diagnostic pathways, and justify capital spending through recurring single-use instrument volumes.
• Intuitive reported about 95,500 Ion biopsy procedures in 2024 against about 53,800 in 2023. Ion procedures then grew roughly 51% in 2025, and the installed base reached 995 systems on December 31, 2025, up 24% from 805 a year earlier, according to the company's SEC filings and earnings release, which shows steady growth in both utilization and placements.

KEY MARKET OPPORTUNITY

Expansion of Robotic Endoluminal Platforms into Gastrointestinal Care and Ambulatory Settings Creating New Revenue Streams

• Gastrointestinal procedures are the largest untapped pool for robotic scope control. Colonoscopy ranks among the most common procedures in many health systems, yet scope looping, missed polyps, and the difficulty of endoscopic submucosal dissection leave clear room for platforms that stabilize the instrument and allow precise two-handed tissue work in a sitting position.
• Ambulatory surgical centers and specialty clinics are a second opportunity. These sites want compact, lower-cost systems that fit small procedure rooms and support quick turnover. Vendors that offer leasing, per-procedure pricing, or bundled single-use kits can open accounts that cannot justify a large upfront capital purchase, and these models also give manufacturers steadier recurring revenue.
• Emerging markets add geographic headroom. Hospitals in China, India, the Middle East, and Latin America are building lung and digestive cancer programs, and local manufacturers are entering with lower-priced systems. Partnerships between global brands and regional manufacturers can shorten registration timelines, bring training closer to new users, and help systems reach hospitals that import channels alone would not serve.
• Olympus and Revival Healthcare Capital co-founded Swan EndoSurgical to develop an endoluminal robotic platform for gastrointestinal treatment. The partners committed an initial USD 65 million, which can rise to as much as USD 458 million as development milestones are met, and Olympus holds an option to acquire the company.

Robotic Endoscopy Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Flexible Robotic Endoscopy Systems held the largest market share in 2025 because they match the procedures where robotics delivers the clearest clinical gain, namely peripheral lung biopsy, upper and lower digestive procedures, and ureteroscopy. Articulating catheters and scopes follow curved anatomy that rigid instruments cannot reach, and navigation software plans the route before the procedure begins. Hospitals have built clinical protocols, training pathways, and payment workflows around flexible platforms, which lowers the barrier to repeat purchases. Single-use scopes and catheters create recurring revenue, so each installed system keeps generating sales long after the initial placement.

Capsule Robotic Endoscopy Systems are projected to grow at the fastest CAGR during the forecast period because magnetic steering turns a passive swallowed capsule into an examination that a physician can direct. The approach needs no sedation, no intubation, and little recovery time, which appeals to screening programs, outpatient clinics, and patients who avoid conventional endoscopy. Better image quality, artificial intelligence reading tools, and wider clearance for stomach and small bowel indications are enlarging the eligible population. Lower procedure costs and the ability to run examinations outside hospital endoscopy suites are encouraging health systems to add capsule robots alongside standard gastroscopy.

Product Type categories include

                       ·           Flexible Robotic Endoscopy Systems (Dominating Segment)

                       ·           Capsule Robotic Endoscopy Systems (Highest CAGR Segment)

                       ·           Rigid Robotic Endoscopy Systems

Analysis by Component

Instruments held the largest market share in 2025 because every procedure consumes single-use catheters, scopes, biopsy tools, or sheaths, so revenue scales with procedure volume rather than with system sales. As installed bases mature, utilization rises and consumables outgrow one-time capital purchases. Hospitals prefer disposables for infection control and predictable performance, since a fresh instrument removes reprocessing steps and wear-related variability. Manufacturers reinforce this position through proprietary instrument designs that work only with their own platforms, which keeps customers inside one ecosystem. Growth in screening-driven biopsy volumes continues to expand recurring demand in bronchoscopy and gastrointestinal procedures.

Software is projected to grow at the fastest CAGR during the forecast period because navigation, planning, and imaging functions now sit at the center of how robotic endoscopy platforms compete. Vendors release regular updates that add artificial intelligence-based lesion segmentation, registration correction, and procedure analytics, and many of these upgrades can be delivered to systems already installed in hospitals. Software also supports video libraries, remote case review, and automated documentation, which help hospitals train staff and standardize care. Subscription and licensing models give manufacturers a steady, high-margin revenue line, and buyers value the ability to improve performance without replacing hardware.

Component categories include

                       ·           Instruments (Dominating Segment)

                       ·           Software (Highest CAGR Segment)

                       ·           Robotic Systems

                       ·           Services

Analysis by Application

Bronchoscopy held the largest market share in 2025 because lung nodule diagnosis was the first application where robotic endoscopy showed a clear improvement over manual method. Small nodules found through CT screening often sit in the outer third of the lung, where conventional scopes struggle to reach and hold a stable position. Robotic platforms give interventional pulmonologists steady control, continuous visualization, and navigation that maps the path to the target. Established coding and payment for navigational bronchoscopy, a growing body of clinical studies, and training programs across large hospital networks have made it the most mature application and the main source of system and instrument revenue.

Gastrointestinal Endoscopy is projected to grow at the fastest CAGR during the forecast period because robotic control addresses long-standing problems in colonoscopy and advanced resection, including scope looping, missed polyps, and the physical strain of endoscopic submucosal dissection. Several flexible platforms for the colon and stomach have reached clinical trials or regulatory clearance, and gastroenterologists represent a very large user base. Colorectal cancer screening programs keep procedure demand high, and the move toward organ-sparing treatment of early tumors creates a clear use for robotic tools inside the digestive tract. Early clinical results are also drawing investment into this application.

Application categories include

                       ·           Bronchoscopy (Dominating Segment)

                       ·           Gastrointestinal Endoscopy (Highest CAGR Segment)

                       ·           Urology

                       ·           Gynecology

                       ·           Others

Analysis by End User

Hospitals held the largest market share in 2025 because robotic endoscopy platforms need capital budgets, imaging suites, trained pulmonology, gastroenterology, and urology teams, and sterile processing support that most large hospitals already have. Tertiary and academic centers run the highest volumes of complex cases, publish the clinical evidence, and serve as training sites for new users. Hospital systems also negotiate multi-unit purchases and long-term service agreements, which raises revenue per customer for manufacturers. Because suspicious lung and digestive lesions are usually referred to hospital-based specialists, these institutions remain the first point of adoption and the largest source of system placements.

Ambulatory Surgical Centers are projected to grow at the fastest CAGR during the forecast period because payers and patients favor lower-cost outpatient settings for diagnostic procedures that do not need an overnight stay. Compact robotic carts, single-use scopes, and shorter procedure times fit the space and staffing limits of these centers. As more biopsy and screening procedures move out of hospital operating rooms, manufacturers are adjusting pricing, training, and financing offers to suit smaller sites. Physician-owned practices also see robotic capability as a way to attract referrals, and this competitive motive supports faster purchasing than in earlier years.

End User categories include

                       ·           Hospitals (Dominating Segment)

                       ·           Ambulatory Surgical Centers (Highest CAGR Segment)

                       ·           Specialty Clinics

                       ·           Others

By Region

Robotic Endoscopy Market Regional Analysis

Robotic Endoscopy Market Share 2025, (CAGR)

North America

62%

South America

XX%

Europe

XX%

Middle East Africa

XX%

Asia Pacific

18%

Regional Analysis

North America held the largest market share in 2025, driven by advanced healthcare infrastructure, high adoption of minimally invasive procedures, and access to innovative endoscopic technologies. The United States leads through investments in robotic-assisted surgery, established cancer screening programs, and the adoption of advanced diagnostic and therapeutic procedures across hospitals and specialized medical centers. Canada contributes through the modernization of hospital facilities and growing adoption of minimally invasive surgical technologies in major healthcare institutions. Mexico presents additional opportunities as private hospitals expand access to advanced endoscopic procedures. Strong clinical capabilities, specialist expertise, and continued healthcare technology investments support North America's leading position.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by large lung and digestive cancer populations, hospital modernization, and a growing roster of locally built systems. China leads the region, with domestic manufacturers registering flexible robotic bronchoscopes, digestive endoscopy robots, and magnetically controlled capsules for use in provincial and city hospitals. Japan and South Korea combine deep endoscopy expertise with early interest in robotic upgrades, while India is expanding private hospital capacity and cancer screening in large cities. Lower-priced domestic systems should widen access beyond tier-one hospitals, making Asia-Pacific the main source of incremental volume.

Countries and Regions Covered

North America (Dominating Region)

o    United States (Largest Country Market)

o    Canada

o    Mexico

Asia-Pacific (Fastest-Growing Region)

o    China (Largest Country Market)

o    India (Fastest-Growing Country Market)

o    Japan

o    South Korea

o    Rest of Asia-Pacific

Europe

o    Germany (Largest Country Market)

o    France

o    United Kingdom

o    Italy

o    Rest of Europe

Latin America

o    Brazil (Largest Country Market)

o    Chile (Fastest-Growing Country Market)

o    Rest of Latin America

Middle East & Africa

o    Saudi Arabia (Largest Country Market)

o    United Arab Emirates (Fastest-Growing Country Market)

o    Rest of Middle East & Africa

Market Share

The Robotic Endoscopy Market is consolidated at its commercial core, with the three FDA-cleared robotic bronchoscopy platforms from Intuitive, Johnson & Johnson, and Noah Medical setting the pace for pricing, evidence, and software features. A wider group of regional and emerging companies competes in gastrointestinal, capsule, urology, and endoscope-positioning niches, which adds a layer of fragmentation. High clinical-evidence requirements, long regulatory clearance cycles, and the cost of building service and training networks protect established players. Key success factors include diagnostic yield data, imaging integration, single-use instrument economics, and software update speed. Leading companies are investing in artificial intelligence navigation, expanding into ambulatory and international markets, and extending platforms to new organs, while partnerships with imaging vendors and funding for gastrointestinal start-ups continue to shape the field.

Key Players

                       ·           Intuitive Surgical, Inc. (US)

                       ·           Johnson & Johnson (US)

                       ·           Noah Medical (US)

                       ·           Neptune Medical (US)

                       ·           Ankon Technologies Co., Ltd. (China)

                       ·           Chongqing Jinshan Science & Technology (Group) Co., Ltd. (China)

                       ·           Shenzhen Edge Medical Co., Ltd. (China)

                       ·           Shanghai MicroPort MedBot (Group) Co., Ltd. (China)

                       ·           PROCEPT BioRobotics Corporation (US)

                       ·           Robo Medical Technology Co., Ltd. (China)

                       ·           AKTORmed GmbH (Germany)

                       ·           Moon Surgical (France)

                       ·           Siemens Healthineers AG (Germany)

                       ·           GE HealthCare Technologies Inc. (US)

                       ·           EndoQuest Robotics, Inc. (US)

Recent Market Developments

• In January 2026, EndoQuest Robotics received US FDA approval to begin the final stage of its PARADIGM pivotal trial for the Endoluminal Surgical System in endoscopic submucosal dissection. The company later reported completing enrollment of 50 robotic procedures across 49 subjects, which moves the platform toward a planned De Novo submission and a potential new option for robotic gastrointestinal resection.
• In August 2026, Noah Medical commercially launched Galaxy II software for its Galaxy System, adding Dual-Mode Imaging that lets physicians switch between high-definition digital tomosynthesis and cone-beam CT at any point in a bronchoscopy. The company states that digital tomosynthesis gives effective imaging in most cases at up to ten times lower radiation dose than cone-beam CT.
• In August 2026, Johnson & Johnson MedTech announced US FDA 510(k) clearance and launch of MONARCH QUEST 3 software, which adds AI-powered lung nodule segmentation, a 3D Compass overlay for scope-tip orientation, and wider compatibility with mobile and fixed cone-beam CT systems. It is the fourth software release for the MONARCH platform in 18 months, a sign of how fast software-led competition is moving.
• In September 2026, Neptune Medical received US FDA 510(k) clearance for its Triton 1 robotic endoscopy system for diagnostic and therapeutic colonoscopy, including endoscopic mucosal resection and endoscopic submucosal dissection. In its 50-patient first-in-human study, the system reached the start of the large intestine in all procedures with no complications and recorded an adenoma detection rate of 54.2%.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Robotic Endoscopy?

2

What is the CAGR of the Robotic Endoscopy Market?

3

Which product type leads the Robotic Endoscopy Market?

4

Which application dominates the Robotic Endoscopy Market?

5

Which component has the highest market share?

6

What are the latest trends in the Robotic Endoscopy Market?

7

Who are the end users of Robotic Endoscopy?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates